Detalhe da pesquisa
1.
A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death.
Immunity
; 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38788712
2.
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment.
Nat Immunol
; 21(2): 120-134, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31873291
3.
Cell-type-specific tumour sensitivity identified with a bromodomain targeting PROTAC in adenoid cystic carcinoma.
J Pathol
; 262(1): 37-49, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37792636
4.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 25(5): 572-587, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38561010
5.
The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK.
Int J Cancer
; 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38685816
6.
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 73(4): 70, 2024 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38430375
7.
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Oncologist
; 27(2): e194-e198, 2022 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641218
8.
Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy.
BMC Med
; 20(1): 16, 2022 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35057796
9.
Methodology for the development of National Multidisciplinary Management Recommendations using a multi-stage meta-consensus initiative.
BMC Med Res Methodol
; 22(1): 189, 2022 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35818027
10.
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lancet Oncol
; 22(4): 450-462, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794205
11.
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
Mod Pathol
; 34(3): 532-541, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33239737
12.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Lancet
; 393(10167): 156-167, 2019 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30509740
13.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Lancet
; 394(10212): 1915-1928, 2019 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31679945
14.
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Lancet
; 393(10166): 51-60, 2019 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30449623
15.
Optimal acquisition scheme for flow-compensated intravoxel incoherent motion diffusion-weighted imaging in the abdomen: An accurate and precise clinically feasible protocol.
Magn Reson Med
; 83(3): 1003-1015, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31566262
16.
The immunological consequences of radiation-induced DNA damage.
J Pathol
; 247(5): 606-614, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30632153
17.
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.
Future Oncol
; 16(18): 1235-1243, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32490686
18.
Prostate-specific membrane antigen expression in melanoma metastases.
J Cutan Pathol
; 47(12): 1115-1122, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32529651
19.
Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Mol Ther
; 27(6): 1139-1152, 2019 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31053413
20.
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Cancer
; 125(18): 3208-3218, 2019 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31246283